Patents by Inventor Rou-fun Kwong

Rou-fun Kwong has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ANTIBODIES AND METHODS FOR WNT PATHWAY-RELATED DISEASES
    Publication number: 20180066067
    Abstract: The transmembrane E3 ubiquitin ligases ZNRF3 and RNF43 are negative regulators of ?-catenin and the Wnt signaling pathway in eukaryotic cells. The activity of ZNRF3 can be modulated by antibody binding to its extracellular domain, thus causing an increase in Wnt signaling. The ZNRF3 antagonizing antibodies can be used to treat diseases with low Wnt signaling, such as short bowel syndrome, osteoporosis, diabetes, neurodegenerative diseases, and mucositis. In addition, the antagonizing antibodies of the invention can be used to enhance Wnt signaling for tissue repair and wound healing.
    Type: Application
    Filed: March 17, 2016
    Publication date: March 8, 2018
    Applicant: NOVARTIS AG
    Inventors: Feng CONG, Huaixiang HAO, Lloyd B. KLICKSTEIN, Rou-Fun KWONG, Ann TAYLOR, Yang XIE
  • Antibodies and methods for WNT pathway-related diseases
    Patent number: 9296826
    Abstract: The transmembrane E3 ubiquitin ligases ZNRF3 and RNF43 are negative regulators of ?-catenin and the Wnt signaling pathway in eukaryotic cells. The activity of ZNRF3 can be modulated by antibody binding to its extracellular domain, thus causing an increase in Wnt signaling. The ZNRF3 antagonizing antibodies can be used to treat diseases with low Wnt signaling, such as short bowel syndrome, osteoporosis, diabetes, neurodegenerative diseases, and mucositis. In addition, the antagonizing antibodies of the invention can be used to enhance Wnt signaling for tissue repair and wound healing.
    Type: Grant
    Filed: October 12, 2012
    Date of Patent: March 29, 2016
    Assignee: NOVARTIS AG
    Inventors: Feng Cong, Huaixiang Hao, Lloyd B. Klickstein, Rou-Fun Kwong, Ann Taylor, Yang Xie
  • TEM8 antibodies, conjugates thereof, and their use
    Patent number: 9181340
    Abstract: Antibodies that specifically bind TEM8 protein, and conjugates thereof, are disclosed herein. In some examples the conjugates and antibodies are useful for methods of detecting and treating pathogenic angiogenesis. In other examples the conjugates and antibodies are useful for methods of detecting and treating cancer. In additional examples, the conjugates and antibodies are useful for methods of decreasing binding of Anthrax protective antigen to a cell.
    Type: Grant
    Filed: June 13, 2012
    Date of Patent: November 10, 2015
    Assignees: The United States of America, as represented by the Secretary, Department of Health and Human Services, Novartis AG
    Inventors: Brad St. Croix, Tony Fleming, Amit Chaudhary, Saurabh Saha, Xiaoyan Michelle Zhang, Rou-fun Kwong, Mary Beth Hilton
  • ANTIBODIES AND METHODS FOR WNT PATHWAY-RELATED DISEASES
    Publication number: 20140328859
    Abstract: The transmembrane E3 ubiquitin ligases ZNRF3 and RNF43 are negative regulators of ?-catenin and the Wnt signaling pathway in eukaryotic cells. The activity of ZNRF3 can be modulated by antibody binding to its extracellular domain, thus causing an increase in Wnt signaling. The ZNRF3 antagonizing antibodies can be used to treat diseases with low Wnt signaling, such as short bowel syndrome, osteoporosis, diabetes, neurodegenerative diseases, and mucositis. In addition, the antagonizing antibodies of the invention can be used to enhance Wnt signaling for tissue repair and wound healing.
    Type: Application
    Filed: October 12, 2012
    Publication date: November 6, 2014
    Applicant: NOVARTIS AG
    Inventors: Feng Cong, Huaixiang Hao, Lloyd B. Klickstein, Rou-Fun Kwong, Ann Taylor, Yang Xie
  • TEM8 ANTIBODIES, CONJUGATES THEREOF, AND THEIR USE
    Publication number: 20140134179
    Abstract: Antibodies that specifically bind TEM8 protein, and conjugates thereof, are disclosed herein. In some examples the conjugates and antibodies are useful for methods of detecting and treating pathogenic angiogenesis. In other examples the conjugates and antibodies are useful for methods of detecting and treating cancer. In additional examples, the conjugates and antibodies are useful for methods of decreasing binding of Anthrax protective antigen to a cell.
    Type: Application
    Filed: June 13, 2012
    Publication date: May 15, 2014
    Applicants: Novartis AG, The United States of America, as represented by the Sec., Dept of Health and Human Services
    Inventors: Brad St. Croix, Tony Fleming, Amit Chaudhary, Saurabh Saha, Xiaoyan Michelle Zhang, Rou-fun Kwong